ASPIRE: Extended DAPT in Peripheral Arterial Disease

Phase 3, randomised trial of clopidogrel and aspirin in Peripheral Arterial Disease (PAD) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death up to 2 years. Started Nov 2015; status: completed.